A few things about the EAP for Remestemcel-L in children with MIS-C (Multisystem Inflammatory Syndrome in Children) (see Mesoblast's PR dated July 6th 2020):
http://investorsmedia.mesoblast.com/static-files/983e69d0-7470-44a1-a72f-8c0dd33d98f71. As I said in one of my earlier posts (
Post #:45669249), I don't think people are understanding the significance of this EAP and what Remestemcel-L can do. This is bigger than ARDS.
2. Many folks are thinking that ARDS is just a bonus and the real big blockbusters are CHF and CLBP. I disagree.
If Remestemcel-L can show that it can treat inflammation (or tame it), then we are talking about the biggest blockbuster that there can ever be.
I think this post from
@tsibis got drowned in the sea of posts but the article he/she posted is a gem. Here is the link to that post -
Post #:45865855And I will post a link to that article:
https://news.sky.com/story/coronavirus-warning-from-italy-effects-of-covid-19-could-be-worse-than-first-thought-12027348If you read and grasp the gravity of that article, you will understand that (and again, like a broken record I will repeat this):
Inflammation is the link to all diseases3. I think many of you have read/heard about "Superbugs".
Well, please read this article by Dr. Julie Gerberding, who was the Director of CDC from 2002 to 2009. She is now the chief patient officer and executive vice president for strategic communications, global public policy, and population health at Merck (yeah, that big pharma company):
https://www.merck.com/about/featured-stories/antibiotic-resistance-the-hidden-threat-lurking-behind-covid-19.htmlThe essence of that article is this:
COVID-19 is a Superbug and is resistant to antibiotics. Even Influenza, SARS and ARDS can be termed as Superbugs and big pharma is running out (if not already run out) of antibiotic treatments. As you probably already know, there is a limit to antibiotic dosage. Worse still, they wreak havoc on the immune system.
4. If the results of the latest EAP for Remestemcel-L in children with MIS-C can show efficacy, I expect another trial to treat adults as well. If that is successful, Remestemcel-L would be a
CURE for all these myltisystem ailments that are caused by
inflammation. Yes, I may be extrapolating but I am doing so based on research and this latest EAP.
5. If you look at the sheer numbers of people affected by inflammation, you will begin to understand the scale and magnitude of the blockbuster for Remestemcel-L. And let's not forget that COVID-19 is here to stay (remember SI said that the "coronavirus is not going away"). So is Influenza. So are other viruses.
As a reminder, I quote from Mesoblast's PR from March 10, 2020:
"Mesoblast’s intellectual property (IP) portfolio encompasses over 1,000 patents or patent applications in all major
markets and includes the use of MSCs obtained from any source for patients with
acute respiratory distress
syndrome (ARDS), and for
inflammatory lung disease due to coronavirus (COVID-19), influenza and other viruses."
http://investorsmedia.mesoblast.com/static-files/c1428818-0b9f-44f9-bb4f-79ad518002ccRepeat business for Mesoblast. Every freaking year from ARDS, Influenza and other viruses.
PS:
@otherperspective Not sure where you got the 12% short interest for MESO (NASDAQ). It is only about 1% as of the latest reporting date of 06/30/2020. It really has been insignificant over the past few years. Only recently it has crept above 1%. It used to be an average of 0.2%. NASDAQ equities report short interest approximately on the 15th and 30th of each month:
https://www.nasdaq.com/market-activity/stocks/meso/short-interestBy the way, institutional holding is still a dismal 2.1% for MESO (I know some of you have given me a breakdown of the holdings, but that is not what I was looking for). I know what the breakdown is. My emails to Mesoblast IR about verifying the institutional holding percentage go unanswered. So I am forced to rely on what the official NASDAQ site provides me with, which is 2.1%
https://www.nasdaq.com/market-activity/stocks/meso/institutional-holdingsIf 2.1% is the correct figure, imagine the
STAMPEDE from US institutions to acquire shares when news comes out about the Phase 3 trial for COVID-19 ARDS.
@favre : You asked me "Can we infer that Mesoblast has put forward a pricing plan for REVASCOR, and that Centene group has in effect agreed that at that pricing, the insurer supports treatment for its customers, once FDA approved?" I do not know the answer to that. I believe that the important thing here is that REVASCOR is already on the insurance providers radars and their listing means that they will cover it.
@TobiasInvest : You asked "forgive me if this is a silly question, but does anybody actually know of any previous examples of drugs appearing on these lists and then failing approval?" Your question was in relation to REVASCOR and Ryoncil appearing on the lists of drugs by Centene/Superior HealthPlan.
It would take an excruciating and time consuming effort to research that. Sorry I do not have that much time.
(20min delay)